Patron-in-Chief, Victorian Governor, the Honourable Linda Dessau AC.

Eliminate hepatitis C Appeal

We are closer than ever to developing an urgently needed hepatitis C vaccine. But in order to get there we need your help.

Donate now to our Eliminate Hep C Appeal

Support Our Work

Eliminate HIV

Ending the HIV epidemic as a public health threat is now a real possibility.

Globally, an estimated 36.7 million people were living with HIV, with 46 percent on life-saving antiretroviral treatment, according to the World Health Organization.

In Australia, more than 26,400 people were living with HIV in 2016 and according to annual HIV surveillance data more than 10 percent were unaware of their HIV-positive status.

The goals of our Eliminate HIV program include:

To facilitate reductions in new HIV infections in Australia and internationally through an improved understanding of the major drivers of transmission.
To work towards HIV elimination by addressing key barriers to the implementation of evidence-based HIV prevention programs, and expanding access to HIV diagnosis and treatment.
Use basic, discovery and translational research to develop, trial and implement new strategies and tools that assist in the prevention, diagnosis and treatment of HIV.

Contact Details

Chad Hughes

Deputy Program Director, Disease Elimination

Telephone

+61392822214

Email

chad.hughes@burnet.edu.au

Projects

A novel biomarker for gut leakage as a diagnostic tool for HIV disease progression
Investigating a novel plasma biomarker's potential for identifying gut leakage.
A novel gel for targeting vaginal inflammation to prevent HIV transmission
Developing an intravaginal gel delivering a vaginal microbiota metabolite.
ACCESS: STI and BBV surveillance system
ACCESS is a surveillance system that collates important information on a range of STIs and BBVs.
Antimicrobial and immune modulatory effects of vaginal microbiota metabolites
Determining the role of vaginal microbiota metabolites in activating HIV and other STIs.
Broadly neutralising anti-HIV antibodies and Fc Receptor function
Defining the properties of anti-HIV antibodies for vaccine development and protection of pregnant women.
co-EC Study: Eliminating hepatitis C/HIV coinfection
Eliminating hepatitis C transmission by enhancing care and treatment among HIV co-infected individuals.
Community-Based Rapid HIV Testing Services
Evaluating a multi-site rapid HIV testing trial in South Australia and rural site in Bendigo, Victoria.
DARE C: ATAHC II Substudy
DARE-C aims to evaluate therapy duration using triple therapy (PEG-IFN/RBV/TPV).
Decision science using Optima
Research and applications across disease areas to improve allocative efficiency.
Developing new HIV disease progression tests
This project will develop prognostic tools to identify HIV+ persons at risk of rapid disease progression.
Development of a novel prophylactic vaccine candidate for HIV-1
A prophylactic vaccine represents the best strategy for blocking HIV-1 transmission.
Development of hydrogel based intravaginal drug delivery device
Developing an intravaginal ring to deliver a microbiota metabolite.
HIV Prevention Cohort
Online cohort study of gay men in Victoria monitoring community-level change.
Impact of a vaginal microbiota metabolite on epithelium integrity and HIV susceptibility
Determining the role of a vaginal microbiota metabolite in enhancing the mucosal barrier to prevent HIV transmission.
Predicting quality and potency of monoclonal and natural antibodies
Rapid, simple and scalable assays for predicting antibody potency.
PrEPX: Rapid scale-up of HIV pre-exposure prophylaxis (PrEP)
Burnet is playing a crucial role in monitoring the outcomes of the PrEPX trial in Victoria.
PRONTO! Rapid HIV point-of-care testing in Victoria
The first rapid HIV test service in Victoria targeting gay men and men who have sex with men.
SHARP: Sexual Health And Risk Prevention Study
Assessing responses to HIV prevention measures among Australian MSM.
TAIPAN: HIV cascade surveillance
Internationally novel project to create a linked surveillance system to monitor the HIV cascade for gay men
Targeting novel sites on reverse transcriptase for HIV treatment and prevention
Discovering a new HIV drug class.

Latest News

11 June, 2019

Later HIV diagnoses for women

New Burnet research shows that women with HIV in Victoria are being tested and diagnosed later than men, with important consequences.
28 May, 2019

Victorian budget investments welcomed

Burnet Institute welcomes the Victorian Government’s announcement of new investments in medical research.

Upcoming Events

21 July, 2019

IAS 2019

Burnet Institute’s Dr Sherrie Kelly will be a Plenary Session speaker at the 10th IAS Conference on HIV Science (IAS 2019) in Mexico.
04 September, 2019

2019 Contemporary Drug Problems Conference

Professor Mark Stoové is an organising committee member for the Contemporary Drug Problems Conference.

Our mission:

To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.

Contact Us

85 Commercial Road, Melbourne
VIC, 3004, Australia

E: reception@burnet.edu.au
T: +61 3 9282 2111

The Hub Site Map Careers

Disclaimer Privacy Policy Complaints Policy

This website was developed with the generous support of a donor.

Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung and Wurundjeri people and we offer our respects to the elders past and present.
We recognise and respect the cultural heritage of this land.

Eliminate hepatitis C Appeal

Support Our Work

Burnet Institute: Medical Research. Practical Action.

Equity through better health

Eliminate HIV